Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S18986 is a selective, orally active, brain-penetrant positive allosteric modulator of AMPA-type glutamate receptors. It has nootropic and neuroprotective effects in animal studies and enhances cognition in rodents by inducing the release of noradrenaline and acetylcholine in the rat hippocampus. S18986 increases the induction and maintenance of long-term potentiation (LTP) in the hippocampus and induces both production of brain-derived neurotrophic factor (BDNF) and AMPA-mediated release of noradrenaline and acetylcholine in the hippocampus and frontal cortex of the brain. Its cognitive-enhancing properties have been demonstrated in various behavioral models including procedural, spatial, "episodic," working, and relational/declarative memory in young-adult and aged rodents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on s18986.